The role of ablative therapy for primary and oligometastatic renal cell carcinoma

Ablation therapy is emerging as a compelling alternate approach for the management of patients with renal cell carcinoma (RCC), particularly patients who are not surgical candidates. These treatment modalities provide an excellent local control and minimal toxicity, with potential to delay systemic therapy for patients with oligometastatic RCC. This review aims to provide an overview of the role of ablative therapies in the management of patients with localized and oligometastatic RCC.